Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658644 | 0.84 | ATF4 (0.82) | ATF4KMT2ALMNAALDH1A1 | |
| SCHEMBL17658585 | 0.84 | ATF4 (0.82) | ATF4KMT2ALMNAALDH1A1 | |
| SCHEMBL20610313 | 0.82 | ATF4 (0.67) | ATF4KMT2A | |
| SCHEMBL20610312 | 0.82 | ATF4 (0.67) | ATF4KMT2A | |
| SCHEMBL20630623 | 0.81 | ATF4 (0.47) | ATF4KMT2AL3MBTL1 | |
| SCHEMBL16082980 | 0.79 | ATF4 (1.00) | ATF4KMT2ALMNAALDH1A1 | |
| SCHEMBL16083047 | 0.79 | ATF4 (1.00) | ATF4KMT2ALMNAALDH1A1 | |
| SCHEMBL16082988 | 0.79 | ATF4 (1.00) | ATF4KMT2ALMNAALDH1A1 | |
| SCHEMBL20631300 | 0.78 | ATF4 (0.77) | ATF4KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL17658709 | 0.78 | ATF4 (0.82) | ATF4KMT2AL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019008506-A1 | N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | WO | disclosed |